Company intelligence / Profile preview

Waterstone Hanxbio Pty Ltd

Western Australia, Australiapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Phase 2

Overview

The company's lead candidate HX009 (anti-PD-1/CD47 bifunctional antibody) has completed Phase I trials in Australia and China and is currently in Phase II trials for advanced solid tumors and relapsed/refractory EBV+ NHL. HX301 (multi-targeted kinase inhibitor) has completed Phase I trials. In February 2025, the company received approval for a Phase 2 trial of HX009 in combination therapy for triple-negative breast cancer.

Therapeutic areas: Oncology
Modalities: Bifunctional antibodiesBispecific antibodies (BsAb)Monoclonal antibodies (mAb)Antibody-drug conjugates (ADCs)Small molecules
Industry: Biotech

Drug pipeline

1 asset

HX009

Partnerships

Hangzhou Hansi Biological Pharmaceutical Co., Ltd.Hangzhou Hanx Biopharmaceuticals, Ltd.

Beyond the preview

Go deeper on Waterstone Hanxbio Pty Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Waterstone Hanxbio Pty Ltd.

Explore the full profile